Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TRASTUZUMAB Cause Malignant neoplasm progression? 957 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 957 reports of Malignant neoplasm progression have been filed in association with TRASTUZUMAB (Trazimera). This represents 2.1% of all adverse event reports for TRASTUZUMAB.

957
Reports of Malignant neoplasm progression with TRASTUZUMAB
2.1%
of all TRASTUZUMAB reports
147
Deaths
132
Hospitalizations

How Dangerous Is Malignant neoplasm progression From TRASTUZUMAB?

Of the 957 reports, 147 (15.4%) resulted in death, 132 (13.8%) required hospitalization, and 20 (2.1%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB. However, 957 reports have been filed with the FAERS database.

What Other Side Effects Does TRASTUZUMAB Cause?

Diarrhoea (4,996) Off label use (3,802) Nausea (3,499) Fatigue (3,417) Myelosuppression (2,552) Disease progression (2,449) Death (2,378) Vomiting (2,244) Dyspnoea (2,010) Pyrexia (1,886)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which TRASTUZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?

TRASTUZUMAB vs TRASTUZUMAB-ANNS TRASTUZUMAB vs TRASTUZUMAB DERUXTECAN TRASTUZUMAB vs TRASTUZUMAB-DKST TRASTUZUMAB vs TRASTUZUMAB-DTTB TRASTUZUMAB vs TRASTUZUMAB EMTANSINE

Related Pages

TRASTUZUMAB Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression TRASTUZUMAB Demographics